For example, Dimitriou and colleagues reported that two patients with BRAFV600-mutant melanoma developed cytokine release syndrome (CRS) after switching to BRAF/MEK inhibitors upon progression on anti-PD-1 ± anti-LAG-3 antibodies [57]. Here, MAP2K7 is linked to melanoma.